Trial Profile
A retrospective study evaluating efficacy of treat and extend treatment regimen in patients switching from pro re nata regimen during routine clinical practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 23 May 2017 New trial record